RE: PYC at 20p a share / £27 Million Mcap is coming....8 Sep 2023 15:09
Quite the contrary Share4. 20p is a real possibility over the next 12-18 months, if not much sooner. It's called due diligence. On June 29, Eli Lilly announced it planned to acquire Sigilon, a small bio for $34.6 million. Sigilon’s stock jumped over 600%. In addition, check out the following information, below, to see why PYC is looking attractive from an investment perspective:
* Dr Peter Sargent joining PYC as Chief Operating Officer. He held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), Among his earlier roles, Dr Sargent was Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.
Then factor in the contract awards that PYC will be winning, guided by Dr Sargent, our miniscule current Mcap of £2.5 million, our tiny share price of 2p ish. When you research the sector, like I do, you will see that PYC is in the right sector at the right time, with big pharmaceutical co’s snapping up smaller rivals for eye watering amounts. Eli Lilly’s Sigilon, deal for $34.6 million is just the tip of the iceberg. See below recent transactions in our space:
* GSK Buys Affinivax for $ 2.10B
* AstraZeneca Purchases CinCor Pharma Inc. in $1.8 Billion Acquisition
* Sun Pharmaceutical Industries Acquires Concert Pharma for $576M
* Envision Pharma Group Acquires OKRA.ai
* GSK Acquires Sierra Oncology in 1 Billion+ deal.
* Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition
* Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics
* Pfizer Buys Global Blood Therapeutics for $5.4B
* Pfizer Acquires ReViral for $525M
* Pfizer Acquires Biohaven Pharmaceutical for $11.6 Billion in Cash
* Sandoz Acquires Drug Delivery Device Company to Boost Pipeline
* Thermo Fisher Acquires PeproTech for $1.85 Billion to Boost Gene Therapy Market
* Pfizer to Acquire Arena for £6.7 Billion to Boost Chronic Disease Management
* Novo Nordisk Enters Pharma Acquisition Deal For RNAi Therapies
Plus, AZ earlier this year paid 1 billion for KYM Bio & also paid $2 Billion to partner Quell Therapeutics. There’s also Lilly’s deal for Versanis for $1.925 billion, SOBiovitrum’s CTI Bio deal for $1.7 billion, Astellas buy out of Iveric Bio for $5.9bn & GSK's £1.6Billion Bellus deal and finally on June 26, Shionogi announced its plans to acquire Qpex Bio for $100 million upfront, with potential for additional payments. These and other billion pound deals for bio minnows are becoming the norm in our sector. This makes being a PYC investor even more compelling. You only have to peruse the recent JP Morgan research note re R&D licencing deals in the pharma sector to see that PYC shareholders could be in for a big pay day in due course. 20p is just for starters. It equates to a Mcap of approx. £27 Million. That’s peanuts in our sector as the above resea
Sign In
Follow the stocks
